UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Clinical trials for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1 trials appear
Sign up with your email to follow new studies for UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second dose of targeted radiation may outperform standard drugs for stubborn gut tumors
Disease control Recruiting nowThis study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…
Matched conditions: UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Double radiation attack may slow tough gut tumors
Disease control Recruiting nowThis early-phase study tests whether adding focused external radiation (SBRT) before a standard radioactive drug therapy (177Lu-DOTATATE) is safe and effective for people with large, inoperable neuroendocrine tumors of the digestive system. About 15 adults whose tumors have grown…
Matched conditions: UNRESECTABLE DIGESTIVE SYSTEM NEUROENDOCRINE TUMOR G1
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC